Sign in Subscribe
Pharmaceutical industry

Generex Biotechnology Corporation Presents at World Congress on Controversies in Obesity, Diabetes, and Hypertension

Strategic Insights

— 2 min read

Generex Biotechnology Corporation, a leader in drug delivery for metabolic diseases, announced its participation in The World Congress on Controversies in Obesity, Diabetes, and Hypertension (CODHy) in Berlin, Germany. The company's executives will make several presentations, including a podium presentation by Dr. Gerald Bernstein on clinical studies related to Generex Oral-lyn, an oral insulin spray product. The conference will focus on significant aspects of diabetes management, including prevention and post-prandial glucose control, and will provide a platform for world-renowned experts to share their experiences and optimize treatments for patients suffering from multiple disorders.

Key Takeaways:

  • Generex Biotechnology Corporation has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
  • The company's flagship product, oral insulin (Generex Oral-lyn(TM)), is in various stages of clinical trials around the world and is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes.
  • The CODHy Congress will focus on prevention and post-prandial glucose control, which are significant aspects of diabetes management that Generex's product pipeline is aimed at addressing.
  • Dr. Gerald Bernstein will present a paper entitled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin."
  • Dr. Jaime Davidson, Generex's Medical Director, will participate in a pre-congress symposium on October 26, 2006, and will make several presentations, including the introduction with a talk entitled "Key Limitations in the Current Therapies for Type-2 Diabetes."
  • The CODHy Congress provides a forum for world-renowned experts to share their experiences and optimize treatments for patients suffering from multiple disorders.

Statistics:

  • Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
  • The company's flagship product, oral insulin (Generex Oral-lyn(TM)), is in various stages of clinical trials around the world.
  • 70% of patients with type-2 diabetes are not able to reach ideal glycemic targets, highlighting the need for more effective treatments.
  • The CODHy Congress has attracted over 1,500 delegates from around the world, making it one of the largest and most prestigious conferences on diabetes management.

Sources:

  • MARKET WIRE via COMTEX, "Generex Biotechnology Corporation Announces Participation in The World Congress on Controversies in Obesity, Diabetes, and Hypertension (CODHy)", October 26, 2006
  • Generex Biotechnology Corporation, www.generex.com, "About Generex"

Read more